ertugliflozin (Steglatro)
Jump to navigation
Jump to search
Indications
- treatment of diabetes mellitus type 2
Dosage
Tabs: 5-mg, 15-mg
Adverse effects
- diabetic ketoacidosis, fracture risk, acute renal failure. increased risk of toe amputation (class effects, rare)
- drug adverse effects of hypoglycemic agents
- drug adverse effects of oral glucosuric agent; SGLT-2 inhibitor; flozin
Mechanism of action
- inhibition of SGLT2, glycosuric
Notes
More general terms
References
- ↑ 1.0 1.1 Busko M FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes Medscape - Dec 21, 2017. https://www.medscape.com/viewarticle/890446
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Terra SG, Focht K, Davies M et al Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017 May;19(5):721-728. Epub 2017 Feb 22. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28116776
- ↑ Rosenstock J, Frias J, Pall D et al Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2017 Aug 31. [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/28857451
- ↑ Dagogo-Jack S, Liu J, Eldor R et al Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo- controlled randomized study. Diabetes Obes Metab. 2017 Sep 17. [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/28921862
- ↑ 5.0 5.1 Cannon CP et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020 Sep 23; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32966714 https://www.nejm.org/doi/10.1056/NEJMoa2004967
- ↑ 6.0 6.1 ACP Diabetes Monthly Newsletter. November 10, 2023